



11TH WORLD CONGRESS ON ALTERNATIVES AND ANIMAL USE IN THE LIFE SCIENCES

*Organising frameworks: AOPs, MOAs and KCs –
Mutually Informative, Not Mutually Exclusive
S104, Monday, August 30*



Modeling the Retinoid System in Biology and Toxicology

Thomas B. Knudsen, PhD

Developmental Systems Biologist

US EPA, Center for Computational Toxicology and Exposure

Chemical Safety for Sustainability (CSS) Research Program

Research Triangle Park, NC 27711

knudsen.thomas@epa.gov

ORCID 0000-0002-5036-596x

DISCLAIMER: The views expressed are those of the presenters and do not reflect Agency policy.

New Approach Methods (NAMs)



- NAMs refer to *in vitro* data and *in silico* models for toxicological assessment with low reliance on animal testing (accelerating data acquisition with fewer resources).
- Healthy pregnancy is an important consideration, that data generated with new testing strategies can be used for developmental hazard evaluation.
- Computational (*in silico*) models that integrate *in vitro* data with knowledge of embryology and development can fill regulatory data gaps for more mechanistic assessments.
- The molecular and cellular determinants of retinoid signaling provide a case study of mutually informative organizing frameworks for NAM-based developmental hazard evaluation.

Can *in vitro* and *in silico* mechanistic tests identify chemicals that perturb development through the retinoid signaling pathway, rather than *in vivo* animal testing?


Regulatory interest in the retinoid signaling pathway

2012: DRP 178 of OECD Test Guidelines Programme highlighted a critical need for harmonized regulations on this system for toxicity screening and evaluation.





2015: OECD EDTA Advisory Group initiated DRP Project 4.97 to review the retinoid signaling pathway across diverse organ systems.

2018: DRP 4.97b narrowed to four areas: Overview, Reproductive System (Annex A), Skeletal Patterning (Annex B), and CNS Development (Annex C).

2021: individual publications in *Reproductive Toxicology* (H Hakannson); final report published in *OECD Testing and Assessment Series No. 343* (P Browne).



Retinoid signaling pathway



- ATRA is locally regulated by a complex network of enzymes, molecular transporters, and nuclear receptors (RARs) determined by cell-specific expression.
- ATRA gradients collaborate with some of the most powerful morphogenetic signals that shape embryonic growth and development (e.g., FGF, BMP, SHH, WNT, ...).
- Local regulation of ATRA homeostasis and its disruption may be captured in diverse AOP frameworks linking molecular initiating events (MIEs) to adverse developmental outcomes.

ATRA thresholds

Regional ATRA concentration thresholds reported in different studies on morphogenesis, differentiation, and pregnancy.

Dosimetric	Conc.	Indication	Reference
baseline ATRA (5 somite zebrafish embryo)	< 1 nM	non-morphogenetic	(Shimozono, Imura et al. 2013)
maternal serum (animal study)	1.7 nM	non-teratogenic	(Daston, Beyer et al. 2014)
devTOX ^{qp} assay (pluripotent hESC)	3.0 nM	teratogenic threshold	(Zurlinden, Sali et al. 2020)
normal plasma concentration	5.0 nM	physiological (adult)	(Napoli, Posch et al. 1991)
axial gradient (5 somite zebrafish embryo)	6.0 nM	morphogenetic signal	(Shimozono, Imura et al. 2013)
endodermal differentiation (h-iPSC)	17 nM	toxicological tipping point	(Sali, Antonijevic et al. 2019)
devTOX ^{qp} assay (pluripotent h-iPSC)	19 nM	DevTox potential	(Palmer, Smith et al. 2017)
genetic perturbation (mouse)	30 nM	altered homeostasis	(Helms, Thaller et al. 1994)
maternal serum (animal study)	30 nM	teratogenic potential	(Daston, Beyer et al. 2014)
limb-bud (GD 10.5 mouse embryo)	30 nM	physiological (embryo)	(Horton and Maden 1995)
pharmacological kinetics	1,000 nM	efficacious (therapeutic)	(Helms, Thaller et al. 1994)
limb-bud (GD 11 mouse embryo)	1,500 nM	weakly teratogenic dose	(Satre and Kochhar 1989)
limb-bud (GD 10.5 mouse embryo)	12,500 nM	fully teratogenic dose	(Horton and Maden 1995)

SOURCE: Knudsen et al. (2021), *Reprod Toxicol*

Information retrieval: *biological targets*



Retinoid Pathway Targets
Retinol Binding Proteins (plasma and cellular transporters)
Molecular transporters for retinol uptake (STRA6, STRA8)
Retinol Dehydrogenase (RDH10)
Retinaldehyde Dehydrogenase (RALDH2)
Cellular Retinoic Acid Binding Proteins (CRABP-I, CRABP-II)
Retinoic Acid Receptors (RARs) alpha, beta, and gamma
Retinoid X Receptors (RXRs) alpha, beta, and gamma
Nuclear Coactivators (NCOAs) and Corepressors (NCORs)
Cytochrome P450 family 26 (CYP26A, CYP26B, CYP26C)

Assemble candidate chemical list for each target:

- ChEMBL has data on 12 metabolic assays for drug-like compounds;
- Bioactivity from high-throughput screening (HTS);
- ToxCast has HTS data on 11 downstream assays testing ~2K chemicals;
- Tox21 has HTS data on an intact retinol signaling pathway for ~10K chemicals;
- Potential disruption of ATRA signaling identified for 213 compounds;
- Literature mining (AbstractSifter v5.7) → 5903 related publications;
- Compile information for pMIEs, key events, and adverse outcomes.

DSSTOXID	PREFERRED_NAME	CYP1A (72)	RARa (65)	RARb (17)	RARg (49)	RXRa (69)	RXRb (299)	RXRg (0)	DM5 (250)
DTXSID10212330	all-trans-Retinoic acid	1.317	NA	NA	NA	NA	1.035	NA	0.050
DTXSID1040619	Bexarotene	NA	7.519	NA	2.655	0.008	0.009	NA	0.014
DTXSID3023556	Retinol	NA	0.075	NA	0.227	2.142	0.464	NA	0.197
DTXSID1020807	2-Mercaptobenzothiazole	0.164	NA	NA	NA	NA	NA	NA	NA
DTXSID0204063	Dimiconazole	0.674	NA	NA	NA	NA	NA	NA	NA
DTXSID0001265	Triconazole	0.798	NA	NA	NA	NA	NA	NA	16.741
DTXSID08024153	Imazalil	1.413	0.908	NA	NA	NA	NA	NA	5.868
DTXSID4032372	Difenoconazole	1.459	NA	NA	NA	NA	NA	NA	2.124
DTXSID3023897	Triadimenon	2.085	41.462	NA	NA	NA	NA	NA	11.223
DTXSID07029871	Clotrimazole	2.306	NA	NA	NA	NA	NA	NA	NA
DTXSID08024235	Flusilazole	3.704	4.155	NA	NA	NA	NA	NA	7.718
DTXSID02032500	Triflumizole	4.134	1.453	NA	NA	NA	NA	NA	0.298
DTXSID00021337	Thiabendazole	4.721	NA	NA	NA	NA	NA	NA	NA
DTXSID08024280	Propiconazole	9.010	23.801	NA	NA	NA	NA	NA	6.253
DTXSID09020453	Dieldrin	NA	0.770	NA	1.679	NA	22.531	NA	0.979
DTXSID09017539	Endosulfan I	NA	1.384	NA	NA	NA	NA	NA	1.827
DTXSID06020561	Endrin	NA	NA	1.606	1.698	NA	24.982	NA	0.806
DTXSID10020560	Endosulfan	NA	NA	NA	NA	NA	NA	NA	0.894
DTXSID07020267	Chlordane	NA	NA	NA	6.878	71.470	21.422	NA	1.784
DTXSID10020560	Isodrin	NA	NA	NA	1.077	NA	NA	NA	2.111
DTXSID08020040	Aldrin	NA	NA	NA	0.912	NA	2.167	NA	1.085
DTXSID03042500	Triphenyltin fluoride	NA	NA	NA	NA	0.004	0.001	NA	0.655
DTXSID05034981	Tributyltin benzoate	NA	NA	NA	NA	0.005	0.036	NA	0.023
DTXSID09044796	(Acryloyloxy)tributylstannane	NA	NA	NA	NA	0.015	0.026	NA	0.022
DTXSID02040733	Triphenyltin chloride	NA	NA	NA	NA	0.081	0.037	NA	0.356
DTXSID09033034	Tributyltin methacrylate	NA	NA	NA	NA	0.347	0.029	NA	0.006
DTXSID03027403	Tributyltin chloride	NA	NA	NA	NA	0.176	0.078	NA	0.003
DTXSID4022153	Tetrabutyltin	NA	NA	NA	NA	0.741	0.033	NA	0.279
DTXSID1021409	Triphenyltin hydroxide	NA	NA	NA	NA	NA	0.013	NA	NA
DTXSID09040712	Triethyltin bromide	NA	NA	NA	NA	4.079	0.752	NA	NA

potency



Retinoids


Triazoles (CYP)

Organochlorines (RAR)


Organotinols (RXR)

HTS data exists for modeling downstream RAR/RXR responses but less available for ATRA metabolism (eg, RDH10, RALDH2, CYP26a/b/c) and molecular transporters (eg, STRA6, CRABP-I, CRABP-II).


Regional domains for ATRA-dependent skeletal patterning




Facial skeleton: positional information of premigratory neural crest cells destined for branchial arches (5- to 11 somite stage).




Vertebral skeleton: size, alignment, and specification of somites giving rise to individual vertebrae/ribs (0- to 36 somite stage).



Appendicular skeleton: limb-bud initiation, outgrowth, patterning, and differentiation (12- to 36+ somite stage).




Putative AOPs for ATRA-dependent skeletal embryopathy




REGION	MIE	KE1	KE2	KE3	KE4	KE5	AO
Anterior Neural Tube	Inhibition of CYP26A1 enzymatic activity	Local increase in endogenous ATRA levels	Hyperactivation of the RAR/RXR heterodimer	Repression of <i>Fgf8</i> limits FGF8 signaling	Mis-specification of CNC cell fate and behavior	Maxillary arch dysplasia alters palatal outgrowth	Cleft palate
Paraxial Mesoderm	Reduction in RDH/RALDH2 activity	Local decrease in endogenous ATRA levels	Hypoactivation of the RAR/RXR heterodimer	Overextension of FGF8 signaling	Disruption of the periodic somitic wavefront	Altered somite number, shape, and alignment	Hemivertebra
Limb-Bud Mesoderm	Hyperactivation of the RAR/RXR heterodimer	Underextension FGF8 signaling from the AER	Dysregulation of <i>Meis1/2</i> and <i>Hox</i> gene expression	Proximalization of the limb-bud mesenchyme	Mis-specification of precartilaginous blastema	Malformed cartilaginous bone rudiment	Phocomelia

Although it is not clear which AOPs may be attributable exclusively to a retinoid-related mechanism, harmonized protocols assessing retinoid signaling can aid developmental hazard prediction.

ToxRefDB chemicals (370) clustered by ToxPi phenotype



- Culled fetal effects data from 2,946 ToxRefDB studies;
- 57,198 skeletal defects across rodent/nonrodent studies;
- clustered chemicals (k=5) by phenotypic domains (ToxPi).



Are fetal skeletal defects consistent with AOPs linked to ATRA pathway?

Mapping potential MIEs to ASOs in the ATRA pathway

Chemicals
(n=117)

In vitro biactivity
(k=8 assays)


Literature
(k=8 assays)

Chemical	Preferred Name	Retinoid Reference	Candidate Reference	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Reference															Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)
----------	----------------	--------------------	---------------------	---------------------	---	--------------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---	---------------------	---





	Retinoid Reference	Candidate Reference	Retinoid Literature	Skeletal Defects (ToxRefDB, Literature)	Pathway	Cyp	RARa	RARb	RARg	RXRa	RXRb	DR5	DevTox	RDH10	
PREFERRED_NAME															
Chlorothalonil						0.472	0.18192163	27.354	NAND	NAND	NAND	NAND	0.185	243	40
all-trans-Retinoic acid						10.335	1.317	0.126	NAND	NAND	NAND	1.036	0.006	4078	902
Imazalil						NAND	1.413	0.908	NAND	NAND	NAND	NAND	5.888	99	11
Pyraclostrobin						NAND	1.678	0.779	NAND	NAND	NAND	NAND	0.542	124	26
Triadimefon						NAND	2.085	41.462	NAND	NAND	NAND	NAND	11.223	139	47
Flusilazole						NAND	3.704	8.155	NAND	NAND	NAND	NAND	7.718	46	19
Triflumizole						NAND	4.134	1.453	NAND	NAND	NAND	NAND	0.298	13	1
Oryzalin						NAND	5.86895958	14.873	NAND	NAND	NAND	NAND	1.116	24	3
Retinol						11.718	NAND	0.076	NAND	0.227	2.142	0.464	0.197	8770	1293

Limb-Bud Mesoderm	Hyperactivation of the RAR/RXR heterodimer	Underextension FGF8 signaling from the AER	Dysregulation of <i>Meis1/2</i> and <i>Hox</i> gene expression	Proximalization of the limb-bud mesenchyme	Mis-specification of precartilagene blastema	Malformed cartilaginous bone rudiment	Phocomelia
-------------------	--	--	--	--	--	---------------------------------------	------------

Example: phocomelia can result when a 30-somite embryo experiences ATRA overload.





Putting an AOP in motion: *loss of SHH signaling impairs limb-bud outgrowth*



Example: mode-of-action for ATRA-mediated limb-bud truncation


Limb-bud initiation requires ATRA signaling but morphogenetic patterning is sensitive to ATRA overload

Several ToxCast compounds inhibit CYP26-like enzymatic activity and weakly activate RAR signaling *in vitro*.



		Retinoid Reference	Cardiac Reference	Retinoid Literature	Skeletal Defects (ToxCast, Literature)	Pathway	Cyp	Rara	Rarb	Rarg	Rora	Rorb	DMS
DSSTOXID	PREFERRED NAME												
DTXSID00020318	Chloromethonil						0.000	27.356	NAND	NAND	NAND	NAND	
DTXSID00040363	Diniconazole						0.674	NAND	NAND	NAND	NAND	NAND	
DTXSID00032655	Triticonazole						0.780	NAND	NAND	NAND	NAND	NAND	16.741
DTXSID0001239	all-trans-Retinoic acid						1.317	0.000	NAND	NAND	NAND	NAND	0.000
DTXSID00024151	Imazalil						1.413	0.000	NAND	NAND	NAND	NAND	5.888
DTXSID00023272	Oribonazole						1.488	NAND	NAND	NAND	NAND	NAND	2.224
DTXSID00034638	Pyridostrobin						1.478	0.000	NAND	NAND	NAND	NAND	0.000
DTXSID00028892	Triadimefon						2.085	41.462	NAND	NAND	NAND	NAND	11.223
DTXSID00033354	Clodinafop-propargyl						2.856	NAND	NAND	NAND	NAND	NAND	
DTXSID00024163	Linuron						3.003	NAND	NAND	NAND	NAND	NAND	
DTXSID00024235	Flusilazole						3.204	8.155	NAND	NAND	NAND	NAND	7.715
DTXSID00034500	Triflumizole						4.134	0.000	NAND	NAND	NAND	NAND	

Simulating an ATRA overload *in silico*: ‘cybermorph’ foreshadows deficiencies of distal elements.



EPA/ORD/CCTE systems model

Predictive Toxicology of the Retinoid Signaling Pathway

Goal: mine HTS bioactivity profiles for the retinoid system and build relevant AOPs based on embryological knowledge for fetal (skeletal) development.

Knowledgebase
(skeletal development)

AOP-WIKI
(limb defects)

HTS-based signatures
(ToxPi classifier)

HTS data analysis
(ToxCast/Tox21/ChEMBL)

Pregnancy IVIVE models
(targeted case studies)

Performance-based prediction
(ATRA pathway in Devtox)

Morphoregulatory simulation
(Limb ABM)

1. Formalize an Adverse Outcome Pathway (AOP) framework for the retinoid system.
2. Map HTS data from relevant assays in ToxCast/Tox21 profiles to the AOP framework.
3. Build and test computational models for quantitative disruption of ATRA signaling.

US EPA, CCTE

Nancy Baker, Leidos
Richard Judson
Thomas Knudsen
Jocelyn Pierro
Ann Richard
Laura Taylor

Tox21 contact

Nisha Sipes, CCTE

NTP/NIEHS

Nicole Kleinstreuer

NIH/NCATS

Srilatha Sakamuru
Menghang Xia

NCTR/FDA

Annie Lumen

OECD

Patience Browne

